BIO-Europe 2024

About

Health Portugal will be present at BIO-Europe, an annual biotechnology meeting held in different European cities since the early 1990s.

The meeting brings together leaders from the biotechnology industry, pharmaceutical companies, investors, and academics to discuss and present the latest trends, innovations, and business opportunities in biotechnology. It is a crucial business platform with clear investment opportunities, where the diversity of exhibitors and insights from promoted sessions are key factors for the event's success.

BIO-Europe 2023 facilitated over 30,000 meetings, hosted more than 5,000 participants, featured over 170 exhibitors, and saw representation from more than 60 countries.

Health Portugal

Health Portugal integrates the national health offer, including the organizations operating in the sector (eg. universities, health care providers, R&D institutes, and companies) and their innovative products and services. The health sector’s main challenges are currently being addressed by a 90M investment project from the Recovery and Resilience Program - Health from Portugal - which aims to provide an integrated response with new opportunities.  

Among the more than 95 solutions being developed, the "Smart Health Solutions" macro-project focuses on pharmaceutical and biotech products and services. These solutions are scheduled to reach the market in early 2026 and include:

• Innovative diagnostics and therapies (Work package 1)

- Optofluidics Device for Blood Sample Analysis- Alzheimer’s disease Drugs and Biomarker Development
- Extracellular Vesicles (EVs) Biomarker Detection Device

• Biomaterials and nanomedicine (Work package 2)

- Advanced Drug Delivery System
- Drug Degradation Measurement Device
 

Contact: 

Joana Feijó | Business Director at Health Cluster Portugal (jfeijo@healthportugal.com) 

Products/Services

Optofluidics Device for Blood Sample Analysis

Optofluidic device as a diagnostic tool using AI algorithms to analyze the optical signature of blood samples. The product will be a highly miniaturized sensor, incorporating optical guides and fluidics, allowing the analysis of biomarkers without the use of reagents, using the combination of different optical signals, for a more effective diagnosis of various types of cancer. 

Alzheimer’s disease Drugs and Biomarker Development

Device for detecting protein biomarkers of Alzheimer's disease by analyzing the optical signature of blood samples and other peripheral fluids using AI algorithms. The product will include the functionalization of plasmonic surfaces to specifically recognize the target molecules and refine the acquired spectroscopy signals.

Extracellular Vesicles (EVs) Biomarker Detection Device

Devices for efficient extraction of extracellular vesicles and specific detection of biomarkers for the prognosis and monitoring of metabolic diseases and conditions associated with chronic inflammation.

Advanced Drug Delivery System

 Advanced bio-based controlled drug release systems for topical and transdermal application, which will result in a comprehensive range of products, such as functional textile structures and bioactive adhesives/pastes for the treatment of acute and chronic wounds, as well as the coadjuvant treatment of chronic diseases such as diabetic foot ulcers.

Drug Degradation Measurement Device 

Monotorization device to assess storange and transportation conditions of medicines to ensure perfect condition for consumption. Different parameters will be measured, including temperature, humidity and UV radiation.